Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs

Pharmaceutical Research

Volumn 13, Issue 2, 1996, Pages 272-278

  Merisko Liversidge, E ^a   Sarpotdar, P ^a   Bruno, J ^a   Hajj, S ^a   Wei, L ^a   Peltier, N ^a   Rake, J ^a   Shaw, J M ^a   Pugh, S ^b   Polin, L ^b   Jones, J ^b   Corbett, T ^b   Cooper, E ^a   Liversidge, G G ^a  

^a NanoSystems   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anticancer agents; Camptothecin; Etoposide; Nanoparticle; Piposulfan and paclitaxel; Poorly water soluble agents

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; ETOPOSIDE; NANOPARTICLE; PACLITAXEL; PIPOSULFAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; DISPERSION; DRUG FORMULATION; DRUG STABILITY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SUSPENSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHEMISTRY, PHYSICAL; CRYSTALLIZATION; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; PARTICLE SIZE; SOLUBILITY; SUSPENSIONS;

EID: 9044235775     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016051316815     Document Type: Article

References (28)

1. J. R. Robinson. Recent advances in formulation of poorly absorbed drugs. In: Current Status on Targeted Drug Delivery to the gastrointestinal tract, pp. 59-63. Capsugel Library, (1993).
2. J. G. Nairn. Solutions, Emulsions, Suspensions and Extracts. In: A. R. Gennaro (ed.), Remington's Pharmaceutical Sciences, pp. 1519-1544. Easton: Mack Publishing Co. (1990).
3. L. M. Slevin. The clinical pharmacology of etoposide. Cancer, 67:319-329 (1993).
4. P. Rubin (ed.) Clinical Oncology. Philadelphia: W. B. Saunders (1993).
5. D. J. O'Dwyer and R. B. Weiss. Hypersensitivity reactions induced by etoposide. Cancer Res, 68:959-961 (1984).
6. J. M. Bennett, G. H. Lymann, P. A. Cassileth, J. H. Glick, M. M. Okem. A phase II trial of VP-16213 in adults with acute myeloid Leukemia. Am. J. Clinic. Oncol. Cancer Clinical Trials, 7:471-473 (1984).
7. M. M. Hudson, H. J. Weinstein, S. S. Donaldson, C. Greenwald, L. Kun, N. J. Tarbell, W. A. Humphrey, C. Rupp, N. M. Marina, J. Wilimas, M. P. Link. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J. Clin. Oncol., 11:1080-1084 (1993).
8. T. M. Allen. Long circulating (sterically stabilized) liposomes for targeted drug delivery. TIPS, 15:215-220 (1994).
9. D. Lasic. Applications of liposomes in pharmacology and medicine. In: Liposomes from physics to applications, pp. 262-471. Amsterdam: Elsevier Press (1993).
10. S. S. Davis, C. Washington, P. West, L. Ilium, G. G. Liversidge, L. Sternson, R. Kirsh. Lipid emulsions as drug delivery systems. Ann N.Y. Acad. Sci. 507:76-78 (1987b).
11. B. Sjostrom, B. Bergenstahl, B. Kronberg. A method for the preparation of submicron particles of sparingly water-soluble drugs by precipitation in oil-in-water emulsions. II: Influence of the emulsifier, the solvent, and the drug substance. J. Pharm. Sci. 82:584-589 (1993).
12. P. Couvreur, L. Roblot-Treupel, M. F. Poupon, F. Brasseur, F. Puisieux. Nanoparticles as microcarriers for anticancer drugs. Adv. Drug Delivery Rev., 5:209-230 (1990).
13. R. H. Muller. In: Colloidal carriers for controlled drug delivery and targeting. Stuttgart: Wissenschaftliche (1991).
14. G. G. Liversidge and K. C. Cundy. Particle size reduction for improvement of oral bioavailability of hyrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J. Pharm (1995, in press).
15. N. Kondo, T. Iwao, H. Masuda, K. Yamamouchi, Y. Ishihara, N. Yamada, T. Haga, Y. Ogawa, K. Yokoyama. Improved Oral Absorption of a Poorly Water-Soluble Drug, HO-221, by Wet-Bead Milling Producing Particles in Submicron Region. Chem. Pharm. Bull. 41:737-740 (1993).
16. T. H. Corbett, D. P. Griswold, B. J. Roberts, J. C. Peckham, F. M. Schable. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat. Reports, 62:1471-1488 (1978).
17. J. L. Grem, K. D. Tutsch, K. J. Simon, D. B. Alberti, J. K. V. Wilson, D. C. Tormey. Phase I study of taxolol administered as a short i.v. infusion daily for 5 days. Cancer Treat. Rep. 71:1179-1184 (1987).
18. J. Koeller, T. Brown, K. Havlin, J. Craig, D. D. Von Hoff. A phase 1 study of taxol given as a 6 hour infusion every 21 days. Invest. New Drug 7:451(1989).
19. D. M. Peereboom, R. C. Donehower, E. A. Eisenhauer, W. P. McGuire, W. P., N. Onetto, J. L. Hubbard. Successful re-treatment with taxol after hypersensitivity reactions. J. Clin. Oncol., 11:885-890 (1993).
20. N. A. Nelson, R. W. Talley, M. L. Reed, A. M. Evans, B. L. Isaacs, P. Huffman, J. Lousi. Midwest cooperative group evaluation of piposulfan (A-20968) in cancer. Cancer Clin. Pharm. Ther. 8:385-391 (1967).
21. J. J. Van Dyk, G. Falkson, H. C. Falkson. Clinical experience with 1,4-dihyracryloylpiperazine dimethanesulfonate (NSC-47774). Cancer Chem. Rep. 52:275-286 (1968).
22. F. M. Muggia, P. J. Creavan, H. H. Hansen, M. H. Cohen, H., O. S. Selawry. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with Preclinical Studies. Cancer Chem. Rep. 56:515-521 (1972).
23. W. J. Slichenmyer, E. K. Rowinsky, R. C. Donehower, S. H. Kaufmann. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:271-291 (1993).
24. K. C. Nicolau, C. Reimer, M. A. Kerr, D. Rideout, W. Wrasidio. Design, synthesis, and biological activity of protaxols. Nature 364:464-466 (1993).
25. I. A. Darwish, A. T. Florence, A. M. Saleh. Effects of hydrotropic agents on the solubility, precipitation and protein binding of etoposide. J. Pharm. Sci. 78:577-588 (1989).
26. G. Borchard, J. Kreuter. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. J. Drug Targeting 1:15-19 (1993).
27. S. E. Dunn, A. Brindley, S. S. Davis, M. C. Davies, L. Illum. Polystyrene-poly(ethylene glycol) PS-PEG 2000 particles as model systems for site specific drug delivery: The effect of PEG surface density on the in vitro cell interactions and in vivo biodistribution. Pharm. Res., 11:1016-1022 (1994).
28. R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, R. Langer. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603 (1994).